期刊文献+

尾加压素Ⅱ对正常及缺血-再灌注离体大鼠心脏的影响 被引量:9

Effects of urotensin Ⅱ on isolated rat hearts under normal perfusion and ischemia-reperfusion
下载PDF
导出
摘要 在正常Langendorff灌流与缺血-再灌注(停灌20 min-复灌20 min)离体大鼠心脏模型,观察尾加压素Ⅱ(urotensin Ⅱ,UⅡ)对冠脉流量、心功能和心肌代谢的影响以及心肌UⅡ受体的功能,以探讨UⅡ的心脏效应。对正常心脏给予0.1、1和10 nmol/L UⅡ各5 min,然后换洗5 min,对停灌缺血-再灌注心脏在再灌注期给予1或10nmol/L UⅡ。监测心率、左室内压和左室内压升降的最大变化率等心功能指标,计算冠脉流量,测定冠脉流出液中总蛋白和肌红蛋白含量以及乳酸脱氢酶(LDH)活性。灌流结束后,测定心肌丙二醛(MDA)含量和质膜UⅡ结合位点(放射性配基结合法)。结果如下:(1)正常心脏灌流UⅡ后,冠脉流量和心功能呈浓度依赖下降,换洗后没有完全恢复。心肌蛋白、肌红蛋白和LDH漏出随UⅡ浓度的增加而增加,换洗后迅速减少。UⅡ组心肌MDA含量与对照组差异无显著性。(2)缺血-再灌注后,冠脉流量显著减少,心功能显著抑制,再灌注期心肌蛋白、肌红蛋白和LDH明显漏出;给予UⅡ后,上述变化增强,且高浓度组更强,与对照组差异有显著性(P<<0.01),再灌注后心肌MDA含量亦显著高于对照(P<0.01)。(3)缺血-再灌注心肌质膜UⅡ受体的B_(max)显著高于正常对照心肌(14.65±1.78vs20.53±1.98 fmol/mg pr,P<0.01),Kd值变化无统计学意义。上述结果表明,在正常? To shed light on cardiac effects of the potent vasoconstrictive peptide urotensin Ⅱ(UⅡ), Langendorff-perfused isolated rat hearts were consecutively perfused with 0.1, 1 and 10 nmol/LUⅡ, for 5 min at each dose, followed by 5-min washout. Moreover, isolated hearts subjected to 20-min global no-flow ischemia were reperfused with UⅡ(1 or 10 nmol/L) for 20 min. Heart function parameters including heart rate, left ventricular pressure and dP/dt were monitored ; content of protein and myoglobin, and activity of lactate dehydrogenase (LDH) in coronary effluent were determined; malondialdehyde (MDA) in myocardium and[^(125)I]-UⅡ binding sites in plasma membrane were measured after the completion of perfusion. The results showed that: (1) In normal rat hearts, the coronary flow was decreased and the heart function was suppressed by U Ⅱ dose-dependently, and these changes were not abolished by washout. The leakage of cardiac protein, myoglobin and LDH increased with the increment of U Ⅱ, but it diminished rapidly after washout. In contrast, MDA content in U Ⅱ-treated myocardium was not statistically different from that in normal myocardium. (2)Ischemia-reperfusion caused significant decreases in coronary flow, suppression of heart function, and leakage of protein and LDH. In UⅡ-reperfused hearts, all these disorders were significantly aggravated and myocardial MDA content significantly increased (P<0.01), to a greater extent in the presence of higher dose of UⅡ. (3) The maximal binding capacity (B_(max)) of UⅡ receptors in plasma membrane from ischemia-reperfusion myocardium increased significantly as compared with that of normal myocardium (20.53±1.98 vs 14.65±1.78 fmol/mg pr, P<0.01), while Kd remained unchanged. These results indicate that UⅡ caused injury to the isolated rat hearts under normal perfusion, and worsened the injury of the hearts under ischemia-reperfusion, in which UⅡ receptors were up-regulated.
出处 《生理学报》 CAS CSCD 北大核心 2003年第4期442-448,共7页 Acta Physiologica Sinica
基金 This work was supported by the Major State Basic Research Development Program of People's Republic of China (No. G2000056905) the 985 Project of Peking University.
关键词 病理学 尾加压素Ⅱ 心脏离体灌流 缺血—再灌注 大鼠 pathology urotensin Ⅱ isolated heart perfusion isehemia-reperfusion rat
  • 相关文献

参考文献21

  • 1Moore G, Letter A, Tesanovic M, Lederis K. Studies on molecular weights d two peptide hormones from the urophysis of white sucker ( Catostomus commersoni ). Can J Biochem 1975 ;53 (2) : 242 - 247.
  • 2Coulouam Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillaln JC, Cordon JM, Bern HA, Vaudry R.Cloning of the cDNA encoding the urotensin lI precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 1998;95(26) :15803 -15808.
  • 3Coulouarn Y, Jegou S, Tostivint H, Vaudry H, Lihrmann I. Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett 1999:457( 1 ):28 - 32.
  • 4Ames RS, Sarau HM, Chambers ,JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ,Hay DW, Douglas SA. Human urotensin-II : a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401(6750):282-286.
  • 5Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams DL, Davidoff M, Wang R, Austin CP, McDonald TP, Bai C, George SR, Evans JF, Caskey CT. Identification of uroteusin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 1999 ;266( 1 ) : 174 - 178.
  • 6Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin II : receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000;131(3) :441 -446.
  • 7Douglas SA, Ashton DJ, Sauermelch CF, Coatney RW,Ohlstein DH, Ruffolo MR, Ohlstein EH, Aiyar NV,Willette RN. Human urotensin-II is a potent vasoactive poptide: pharmacological characterization in the rat,mouse, dog and primate. J Cardiovasc Pharmacol 2000;36(5 Suppl 1) :S163 - S166.
  • 8Bottrill FE, Douglas SA, Hiley CR, White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 2000;130(8) :1865 -1870.
  • 9Kntano Y, Ishihata A, Aim T, Ogaki T, Horie T. Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmecol 2000 ;402(1-2) :R5-R7.
  • 10Russell FD, Molenaar P, O'Brien DM. Cardiostimulant effects of urotensin- II in human heart in vitro. Br J Pharmacol 2001; 132(1) :5 -9.

同被引文献138

引证文献9

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部